Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

US Court of Appeals Affirms District Court Decision That Biogen's 2028 Tecfidera Patent is Valid

11/30/2021 | 11:12am EST


ę MT Newswires 2021
All news about BIOGEN INC.
03:46aBiogen to Sell Equity Stake in Samsung Bioepis JV to Samsung Biologics for Up to $2.3 B..
MT
01/27Samsung Biologics to acquire stake worth $2.3 billion in Samsung Bioepis
RE
01/27Samsung Biologics to Buy Biogen's Stake in JV
DJ
01/27Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimila..
GL
01/27Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimila..
GL
01/27Health Care Flat Amid Defensive Bias -- Health Care Roundup
DJ
01/27Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM«
AQ
01/24SVB Leerink Adjusts Biogen's Price Target to $300 from $325, Keeps Outperform Rating
MT
01/21Alzheimer's patient groups protest U.S. Medicare coverage proposal limiting use of new ..
RE
01/20Barclays Adjusts Biogen's Price Target to $244 from $280, Keeps Equalweight Rating
MT
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2021 10 866 M - -
Net income 2021 1 619 M - -
Net Debt 2021 2 281 M - -
P/E ratio 2021 20,4x
Yield 2021 -
Capitalization 32 161 M 32 161 M -
EV / Sales 2021 3,17x
EV / Sales 2022 3,03x
Nbr of Employees 9 100
Free-Float 85,4%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 34
Last Close Price 218,94 $
Average target price 287,21 $
Spread / Average Target 31,2%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Mark Hernon Chief Information Officer & Senior Vice President
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Sector and Competitors
1st jan.Capi. (M$)
BIOGEN INC.-8.74%32 161
CSL LIMITED-14.20%84 148
WUXI BIOLOGICS (CAYMAN) INC.-16.59%41 757
ALEXION PHARMACEUTICALS, INC.0.00%40 336
SAMSUNG BIOLOGICS CO.,LTD.-21.15%39 159
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-13.07%27 227